myirislogo
18 April, 2015 10:22 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Icici Bank 310.10 0.69
Hindalco In 139.80 1.86
Axis Bank 534.15 3.23
Tata Stl 345.85 2.53
State Bank O 291.05 0.14
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Cipla Limited
Cipla Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
BSE:500087NSE:CIPLABloomberg:CIPLA@INReuters:CIPL.BO
Market Lot: 1Face Value: 2ISIN Demat: INE059A01026
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
25-MAR-15 Cipla today announced the launch of generic drug Sofosbuvir in India under the brand name 'Hepcvir'. 04-MAR-15 Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the United States Patent and Trademarks Office (USPTO) granted a US process patent for its novel stem-cell based drug Stempeucel. 13-FEB-15 Cipla, leading drug maker, announced that it ha...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Cipla launches generic drug Sofosbuvir in India  -IRIS 25-Mar-15
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Dec-2014(9)31-Mar-2014 (12)31-Mar-2013 (12)
Net sales 70759.7090349.5080153.70
Other Income1071.602802.802291.30
Total Income71831.3093152.3082445.00
Cost of goods sold58622.2073907.6060832.80
OPBDIT13209.1019244.7021612.20
PAT9671.9013883.4015071.10
Gross Block---
Equity capital1605.801605.801605.80
EPS (Rs.)-17.2918.77
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-21.06 - 26.0316.02 - 23.18
Debt / Equity (x)---
Operating margin (% of OI)18.420.726.2
Net margin (% of OI)13.514.918.3
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Mumbai Central
Mumbai
Maharashtra-400 008
PHONE
(022) 2309 5521 / 2302 5272
FAX
(022) 2300 8101
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer